Results 231 to 240 of about 288,727 (306)

What are the common musculoskeletal side effects associated with tyrosine kinase inhibitors, particularly in the lower leg and thigh?

Tripdatabase
openalex   +1 more source

The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic cell transplantation (allo‐HCT) is an effective treatment for patients with high‐risk hematologic malignancies. Over the last decade, gut microbiota composition during allo‐HCT has been associated with patients' outcomes.
Wenjing Hao, Nicolas Stocker, Béatrice Gaugler, Mohamad Mohty, Florent Malard   +4 more
wiley   +1 more source

Mechanisms, Clinical Phenotype and Potential Risk Prediction for Cardiovascular Toxicity Induced by Tyrosine Kinase Inhibitors In Chronic Myeloid Leukemia. [PDF]

Dose Response
Zheng H, Huang C, Zhang Z, Su M, Jiang P, Wu G.   +5 more
europepmc   +1 more source

Figure S6 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in <i>EGFR</i>-Mutant Lung Cancer

TongYan LIU, Shiyi Huang, Zhitong Li, Jianyu Li, Qinhong Sun, Qinglin Wang, Ziyang Shen, Zhijun Xia, Fanchen Meng, Youtao Xu, Wenjia Xia, Jing Tan, Rong Yin   +12 more
openalex   +1 more source

The 9th International RASopathies Symposium

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel, Lisa Schoyer, Beth Stronach, Raya Bogdanova, Anton M. Bennett, Jaishri Blakeley, Miriam Bornhorst, Tammy Bowers, Saskia M. Brachmann, Emma Burkitt‐Wright, Kathryn Chatfield, Alessandro De Luca, Khalil El‐Chammas, Abdul Elkadri, John E. Fortunato, Bruce D. Gelb, Anne Goriely, Karen Gripp, Kassidy Grover, Lindsay Homan, Kenneth A. Kern, Maija Kiuru, Charles (Chuck) Lawson, Yong‐Seok Lee, Frank McCormick, Gina Ney, Cristina Nuevo‐Tapioles, Sara Pardej, Elizabeth I. Pierpont, Julia Plank, Nancy Ratner, Katherine A. Rauen, J. Elliott Robinson, Les Rogers, Sarah E. Sheppard, Keir Shiels, David Stevenson, Dagmar Tiemens, Matthew Traylor, K. Nicole Weaver, Marielle Yohe, Tamar Green   +41 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +1 more source

Table 1_Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study.docx

Jinhan Chen (13866923), Qian Xu (119888), Bozhou Wang (1434532), Huiwen Sun (11262205), Qijin Shu (12447588)   +4 more
openalex   +2 more sources

Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley   +1 more source

Animal models of chronic thromboembolic pulmonary hypertension

Animal Models and Experimental Medicine, EarlyView.
Current animal models of CTEPH. Created using BioRender.com. Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, yet life‐threatening disorder characterized by persistent pulmonary vascular obstruction and elevated pulmonary artery pressure, with progressive remodeling and subsequent right heart failure.
Yong‐Jian Zhu, Lin‐Chao Zhou, Xiao‐Xue Zhang, Xiao‐Yang Ren, Yi Yan, Shao‐Fei Liu   +5 more
wiley   +1 more source

Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia. [PDF]

Cancer Chemother Pharmacol
Verhagen NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, Blijlevens NMA, Janssen JJWM, Koenderink JB, Russel FGM.   +7 more
europepmc   +1 more source